Role of biomarkers in early diagnosis and prognosis of cardiac amyloidosis: A systematic review and meta-analysis.

Curr Probl Cardiol

Lung Transplant Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Published: January 2025

AI Article Synopsis

  • Cardiac amyloidosis involves amyloid deposits in the heart, leading to serious conditions like heart failure, making early diagnosis important for treatment.
  • A systematic review analyzed studies on biomarkers to detect and track cardiac amyloidosis, focusing on their diagnostic and prognostic value.
  • Key findings highlighted that NT-proBNP and troponins are effective for early detection, while new biomarkers may help differentiate subtypes and predict disease progression, though results varied with imaging correlations.

Article Abstract

Background: Cardiac amyloidosis is characterized by amyloid fibril deposition in the heart, leading to restrictive cardiomyopathy and heart failure. Early diagnosis and monitoring are crucial for effective management. This systematic review and meta-analysis evaluates the utility of various biomarkers in the early detection, disease progression, and prognosis of cardiac amyloidosis.

Methods: We conducted a comprehensive search of PubMed, Scopus, and Web of Science databases for studies published between 2000 and 2024 that assessed the diagnostic and prognostic value of biomarkers in cardiac amyloidosis. Data were extracted and analyzed to determine the sensitivity, specificity, and prognostic significance of each biomarker. The correlation between biomarker levels and imaging findings was also explored.

Results: A total of 45 studies were included in the meta-analysis. NT-proBNP and troponins had high sensitivity and specificity for early diagnosis of cardiac amyloidosis. Novel biomarkers, such as serum amyloid P component and light-chain assays, showed promise in distinguishing between amyloidosis subtypes and predicting disease progression. However, significant variability existed in the correlation between biomarkers and imaging findings.

Conclusions: Biomarkers are crucial for early diagnosis and prognosis of cardiac amyloidosis. NT-proBNP and troponins are well-established markers, while novel biomarkers offer additional insights into disease progression and subtype differentiation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2024.102883DOI Listing

Publication Analysis

Top Keywords

cardiac amyloidosis
20
early diagnosis
16
prognosis cardiac
12
disease progression
12
biomarkers early
8
diagnosis prognosis
8
systematic review
8
review meta-analysis
8
sensitivity specificity
8
nt-probnp troponins
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!